Company / Cash & Equivalents
Solid Biosciences Inc. Cash & Equivalents History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$119.1M
FY2022
5-year range
$52.1M / $119.1M
FY2018-FY2022
Trend
+56.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $86M to $119M over the past 2 years.
Based on SEC 10-K filings.
$119M in FY2022 with a 3-year CAGR of +11.3%.
Improved from $86M to $119M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +11.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +11.3%, indicating consistent growth.
- In FY2022, cash & equivalents increased 56.7% year-over-year.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $119.1M | +56.7% |
| FY2021 | $76.0M | -12.0% |
| FY2020 | $86.4M | +0.0% |
| FY2019 | $86.4M | +65.8% |
| FY2018 | $52.1M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026